Table 1.
Clinical characteristics.
| Characteristics | All cases | EGFR-TKIs’ PFS<10m | EGFR-TKIs’ PFS≥10m | p |
|---|---|---|---|---|
| Total, n | 58 | 26 | 32 | |
| Median age(range), y | 58.8 (21–80) | 57.9 (21–76) | 59.6 (25–80) | |
| Age group, n (%) | 0.128 | |||
| <65 years | 39 (67.2) | 20 (76.9) | 19 (59.4) | |
| ≥65 years | 19 (32.8) | 6 (23.1) | 13 (40.6) | |
| Gender, n (%) | 0.438 | |||
| Male | 25 (43.1) | 12 (46.2) | 13 (40.6) | |
| Female | 33 (56.9) | 14 (53.8) | 19 (59.4) | |
| Smoking history, n (%) | 0.365 | |||
| Never-smoker | 49 (84.5) | 21 (80.8) | 28 (87.5) | |
| Former/current smoker | 9 (15.5) | 5 (19.2) | 4 (12.5) | |
| ECOG performance status, n (%) | 0.119 | |||
| 0-1 | 53 (91.4) | 22 (84.6) | 31 (96.9) | |
| 2 | 5 (8.6) | 4 (15.4) | 1 (3.1) | |
| Pathological classification, n (%) | 0.611 | |||
| Adenocarcinoma | 54 (93.1) | 24 (92.3) | 30 (93.8) | |
| NSCLC NOS | 4 (6.9) | 2 (7.7) | 2 (6.2) | |
| TNM stage, n (%) | 0.389 | |||
| III | 4 (6.9) | 1 (3.8) | 3 (9.4) | |
| IV | 54 (93.1) | 25 (96.2) | 29 (90.6) | |
| EGFR mutation type, n (%) | 0.511 | |||
| 19DEL | 28 (48.3) | 13 (50.0) | 15 (46.9) | |
| L858R | 30 (51.7) | 13 (50.0) | 17 (53.1) | |
| Required T790M mutation, n (%) | 0.356 | |||
| Yes | 13 (22.4) | 4 (15.4) | 9 (28.1) | |
| No Unknown |
37 (63.8) 8 (13.8) |
17 (65.4) 5 (19.2) |
20 (62.5) 3 (9.4) |
|
| Type of EGFR-TKIs, n (%) | 0.512 | |||
| Gefitinib | 30 (51.7) | 11 (42.3) | 19 (59.4) | |
| Erlotinib | 15 (25.9) | 7 (26.9) | 8 (25.0) | |
| Icotinib | 13 (22.4) | 8 (30.7) | 5 (15.7) | |
| Best response to EGFR-TKI, n (%) | 0.005 | |||
| PR | 40 (68.9) | 13 (50.0) | 27 (84.4) | |
| SD/PD | 18 (31.1) | 13 (50.0) | 5 (15.6) | |
| Distant metastasis, n (%) | 0.389 | |||
| Yes | 54 (93.1) | 25 (96.2) | 29 (90.6) | |
| No | 4 (6.9) | 1 (3.8) | 3 (9.4) | |
| No. of immunotherapy line, n (%) | 0.245 | |||
| 2 | 25 (43.1) | 13 (50.0) | 12 (37.5) | |
| ≥3 | 33 (56.9) | 13 (50.0) | 20 (62.5) | |
| Treatment regimen, n (%) | 0.587 | |||
| αPD-1/PD-L1 monotherapy | 7 (12.1) | 4 (15.4) | 3 (9.4) | |
| αPD-1/PD-L1 + Chemo | 47 (81.0) | 21 (80.8) | 26 (81.3) | |
| αPD-1/PD-L1 + Apatinib | 4 (6.9) | 1 (3.8) | 3 (9.4) | |
| PD-L1 expression, n (%) | 0.186 | |||
| Not detected | 24 (41.4) | 12 (46.2) | 12 (37.5) | |
| Negative | 17 (29.3) | 5 (19.2) | 12 (37.5) | |
| 1–49% | 11 (18.9) | 6 (23.1) | 5 (15.6) | |
| ≥50% | 6 (10.4) | 3 (11.5) | 3 (9.4) | |
| Local therapy, n (%) | 0.611 | |||
| Yes | 11 (19.0) | 5 (19.2) | 6 (18.8) | |
| No | 47 (81.0) | 21 (80.8) | 26 (81.3) |
ECOG, eastern cooperative oncology group; EGFR-TKIs, epidermal growth factor receptor; NSCLC, non-small-cell lung cancer; NOS, not otherwise specified; No, number; Chemo, chemotherapy.